HP-3180

HP-3180 is a transdermal patch formulation of fesoterodine, a muscarinic acetylcholine receptor antagonist, being developed by Hisamitsu Pharmaceutical for the treatment of overactive bladder (OAB). Fesoterodine is a prodrug that is rapidly hydrolyzed to its active metabolite, 5-hydroxymethyl tolterodine (5-HMT), which acts as a competitive antagonist at muscarinic receptors in the bladder detrusor muscle. By inhibiting these receptors, the active metabolite suppresses involuntary bladder contractions, thereby reducing symptoms of urgency, frequency, and urge incontinence. The transdermal delivery system is designed to provide sustained drug release, potentially improving patient compliance and tolerability by avoiding the peak plasma concentrations associated with oral administration. As of 2024, HP-3180 is in Phase 1 clinical development in Japan.

Other names

fesoterodine transdermal patch